No match found
No compound matched this term. SynDRA covers 3M+ compounds — try a generic name, brand name, INN, research code, or a database ID (ChEMBL, DrugBank, PubChem CID, InChIKey, RxNorm RXCUI).
More complete than any single source
Diverse recall across a 4-domain benchmark (rare/orphan drugs, CNS, cardiovascular, FAERS noisy names). SynDRA integrates all sources; 94.2% plain-match recall, 100% with the full resolver.
| Source | Recall ↑ | Compounds | Redistributable |
|---|---|---|---|
| PRISM | 18.2 % | ~5 K | Yes |
| LINCS 2020 | 54.4 % | ~13 K | Yes |
| TTD | 74.8 % | ~8 K | Yes |
| ChEMBL | 82.8 % | ~2.4 M | Yes |
| DrugCentral | 83.6 % | ~3.7 K | Yes |
| PubChem | 85.8 % | ~95 M | Yes |
| SynDRA (all sources) | 100.0 % | 3,112,548 | Yes |
Benchmark: 274-drug diverse gold set (rare/orphan, CNS/neuropsychiatric, cardiovascular with salt forms, FAERS noisy real-world names); recall = fraction of benchmark drugs recovered via name or identifier. Best single source: PubChem 85.8%; SynDRA reaches 100% (+14.2 pp) using multi-source integration and resolver fallbacks.
The same drug, scattered across names and identifiers, reassembled.
SynDRA integrates synonyms from LINCS 2020, TTD, PRISM, DrugCentral, DrugBank, PubChem, ChEMBL, UniChem, and RxNorm, then anchors every name to a standardized InChIKey so that salts, solvates, and stereoisomers of one molecule all resolve to the same canonical compound. Two live diagrams below use one real compound from the current build — sirolimus (rapamycin), SYN0000068 — to show exactly how.
Same drug, nine names, one ID
Each database knows this molecule by a different string — a brand name, a vendor code, an internal accession. Click below to watch them all snap onto one structure-anchored node.
Same molecule?
HPLJOQBZSA-N
Nine databases, nine different strings for the same molecule — one InChIKey ties them together.
Real record from the current build (redistributable slice: 320 synonyms, 6 xref-contributing sources). †DrugBank/RxNorm identifiers are cross-referenced through other sources here — their own license-restricted records aren't redistributed. ‡LINCS profiles this compound on a not-yet-merged stereo-variant node — a real gap the reconciliation pipeline hasn't closed.
Follow one query, start to finish
A brand name, a research code, a database accession, or a typo — the same six-stage path lands on the same record.
Harmonize names
Synonyms and identifiers from nine core sources plus Wikidata and FDA Orange Book are Unicode-normalized and resolved to one canonical node, keyed by a stable SynDRA ID. Name-only entries are kept, never dropped.
Anchor to structure
RDKit desalts, charge-neutralizes, and derives a full InChIKey for each compound. Salts, solvates, and stereoforms of one molecule share a connectivity skeleton and link automatically.
Annotate and enrich
Targets, mechanisms of action, indications, ATC classes, and clinical phases are harmonized across 14 annotation sources and deduplicated to canonical terms.
Resolve noisy queries
Exact → prefix → fallback chain strips dose, salt, combination, and vendor-code suffixes. The same chain that lifts real-world name recall to 100% in benchmarking runs in your browser on every search.
Browse drugs
Filter the compound hub by target, mechanism of action, indication, ATC class, clinical development phase, FDA approval status, or first-approval country. Filters combine with AND — narrow by any combination to find candidates.
Source databases
SynDRA harmonizes nine core synonym/structure databases plus two enrich-only extensions. Every compound record links back to the original source below. See DATA_SOURCES.md for exact file versions and download dates.
†DrugBank and RxNorm identifiers are cross-referenced through other sources in the redistributable build — their own license-restricted records aren't redistributed.
Annotation & enrichment sources (targets, mechanisms, indications, ATC, clinical phase):
Built on the full SynDRA map
The complete resource, build pipeline, and structural validation are open on GitHub. Cite SynDRA if it supports your work.